drugset / Trial / NCT01209195

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195

Phase 1 Completed 41 enrolled Merrimack Pharmaceuticals Sanofi · collab
NaSingle-groupOpen-labelTreatment

Summary

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.

Timeline

Start
2010-10
Primary completion
2014-05
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Seribantumab Monoclonal antibody Intravenous
Background Paclitaxel Small molecule 80 mg/m2 Intravenous